Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
ConclusionIn Chinese HFpEF patients, adding empagliflozin to standard treatment is cost-effective, but studies based on real-world data are needed.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | China Health | Empagliflozin | Heart | Heart Failure | Jardiance | Study